Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Biocept (BIOC) Prices 22.3M Share Registered Direct Offering of Common Stock at $0.46/sh
-
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
-
Biocept (BIOC) Announces Pricing of $6.6 Million Registered Direct Offering of Common Stock
-
Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market
-
Biocept (BIOC) Prices 23M Share Registered Direct Offering at $0.40/Sh
-
Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market
-
Biocept Announces Closing of $10.0 Million Underwritten Public Offering
-
Biocept (BIOC) Announces Pricing of $10 Million Underwritten Public Offering of Common Stock, Warrants
-
Biocept Announces Pricing of $10.0 Million Underwritten Public Offering
-
Pre-Open Stock Movers 03/26: (ALDX) (BBBY) (BIOC) Higher; (CCL) (MYOK) (RCL) Lower (more...)
-
Maxim Group Starts Biocept (BIOC) at Buy
-
Biocept (BIOC) Prices 5.95M Share Registered Direct Offering for Gross Proceeds of $8.2M
-
Biocept Announces Pricing of $8.2 Million Registered Direct Offering
-
Biocept (BIOC) Prices $7.5 Million Underwritten Public Offering of Common Stock and Warrants
-
Biocept Announces Pricing of $7.5 Million Underwritten Public Offering
-
Biocept (BIOC) Prices $2.2M Registered Direct Common Share Offering
-
Biocept Announces Pricing of $2.2 Million Registered Direct Offering
-
Biocept (BIOC) Reports $2.5 Million Registered Direct Offering of Common Stock, Warrants Priced at Market
-
Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
-
Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
-
Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
-
Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
-
Unusual 11 Mid-Day Movers 10/14: (CTRV) (FBMS) (MGT) Higher; (OPTT) (TAYD) (BIOC) Lower

